Zambon is a modern multinational pharmaceutical and fine-chemical group founded on the heritage and values of an innovative Italian family-owned enterprise that over the years has earned a strong reputation for high quality products and services. Zambon is headquartered in Milan and was established in 1906 in Vicenza. Zambon is present in 19 countries with subsidiaries in 5 continents and 2,800 employees.
In 2016 revenues amounted to 713 million euro with 600 million euro sales from the pharmaceutical business. Zambon is well-established in 3 therapeutic areas: respiratory, pain and women’s health, and is committed to developing medicines to make patients’ lives better in specialty areas and rare disease such as Parkinson’s disease and cystic fibrosis.
The group is active throughout the drug production chain with Zach - Zambon Chemicals for API (active ingredients), generics and custom products with €147 million sales in 2016 and manufacturing units in Italy, Switzerland, France, China and Brazil. ZCube, the research venture of the Zambon Group, supports and invests in innovative ideas in the fields of drug delivery, medical devices and digital health from early stages up to market launch. In 2016 ZCube launched the first made-in-Italy fast track acceleration program dedicated to projects in the life sciences. The Group provides also patient support programs (PSPs) through Italiassistenza, the first nationwide qualified healthcare and homecare network for the elderly and the disabled and disabled. Zambon products are commercialized in 84 countries. For details on Zambon please see: www.zambongroup.com